Rafael Amado: This is Rafael. Just want to — wanted to go over the second part of the question. And just briefly, NovoCure has made public that they expect to submit a PMA or pre market approval application with the U.S FDA, which by the end of — on the second half of this year, that’s the equivalent of the NDA for drugs. So our plan is to follow on the submission and submit following the U.S submission in China. So the timing of as we work with our partner for the exact timing of the submission in the U.S., but we will follow very closely the U.S submission. And then obviously, there’s no PDUFA timeline in China. But we work with the authorities to try to accelerate the approval as soon as possible. So we expect that this potentially could be approved in the not too distant future, and the file will be imminent after the U.S file.
Ziyi Chen: Got it. Thank you.
Operator: Thank you for your question. We are now taking the next question. Please stand by. And the next question from Seamus Fernandez from Guggenheim Partners. Please go ahead. Your line is open.
Seamus Fernandez: Great. Thanks for the question. So just two quick questions. Can you — team if you could just walk us through how you see the KarXT opportunity evolving? I think Billy, you specifically stated that you feel this particular program is under appreciated. And just again, from that SG&A spend perspective, what do you think is necessary to really effectively promote KarXT to kind of maximize the opportunity? And then just a second quick question, as we think about the Tumor Treating Fields opportunity, obviously manufacturing to support this potential size of that market opportunity is going to be important. Can you just help us understand how you’re going to approach that opportunity from a manufacturing perspective? Thanks.
Billy Cho: Hey, Seamus, thanks for your question. I’ll provide the manufacturing question to Josh. For your question on KarXT, the — you’re right. I did say people are underestimating the potential in China and we believe that there are more than 8 million people in China living with schizophrenia today. And we believe in this product. And we think that it’s got a potential to treat multiple symptom domain as monotherapy, or even adjunctive. So really the — and out of the 8 million people, we know that 8 — 4.3 million people are diagnosed with severe forms of schizophrenia in the national database. So these are truly significant figures. And so — and I think I hear my colleague, Harald, kind of clearing his throat, because I think he may be adding some comments here and there, but feel free to chime in Harald, on the potential impact of KarXT on a kind of the size of China.
Harald Reinhart: Yes, thank you. Thank you for the question, too. It’s clear that when the in-licensed KarXT, we were really keen on bringing something to China, which is differentiated. We have and see in KarXT in two studies now in the EMERGENT studies, that this drug is addressing the negative symptoms that are really difficult to treat with existing pharmaceuticals. So that was one major differentiating feature. The second one was the side effect profile, this is a totally different class of drugs. And that alone is an important piece to remember, because most of the other antipsychotics for schizophrenia, they do come from the serotonin dopamine series, and have a certain side effect profile, which is really problematic.
That’s one of the reasons why a lot of patients do not continue treatment. As far as the addressable patient population, there is a significant unmet need in the patients with schizophrenia, just because the negative symptoms are not adequately treated at this point in time. So we see this as a global issue. But we see it also in China, where there is a need to bring more psychiatric help to patients who are currently underserved. There is a government drive to increase the numbers of psychiatrists and to help patients out with schizophrenia, much more so than in the past. So from our perspective, we see a significant market potentially in China. And we see it in a patient group that currently has very few options. Thank you.
